Zerion Pharma< A/S (“ZERION”) today announces a partnership with Aché Laboratorios Farmacêuticos S.A. (“ACHÉ”), a major Brazilian pharmaceutical company. The partnership is aimed at taking advantage of ZERION’s expertise and its Dispersome® technology for improving the formulation of two drug products in the oncology and neuroscience areas that are currently marketed across the world, each with revenue in the billion-dollar range.
Under the collaboration, ZERION ’s Dispersome® technology will be applied to develop more patient-friendly formulations of the drug products with the aim of increasing their solubility and bioavailability as well as drug loading. As a result, the patients will benefit from reducing their daily pill burden. One of the drug products has already been developed to the prototype stage by ZERION and investigated in animal studies. The other product is a new target for the Dispersome® technology and will be subject to an initial feasibility study.
Under the agreement, ACHÉ is granted exclusive rights to sell and market the Dispersome® drug products in Latin American countries (LATAM). Outside LATAM, the two companies will work together to commercialize and secure patient access to the improved drug products.
“We are very pleased to have entered this partnership with Aché, which we consider a true first mover and one of the most innovative and patient-focused companies in Latin America. I am grateful for Aché’s confidence in our technology and competencies and convinced that our collaboration will be successful in bringing better drug products to the market not only in Latin America but on a global scale”, says Ole Wiborg, CEO of Zerion Pharma.
